47 related articles for article (PubMed ID: 25620533)
1. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Butrym A; Rybka J; Baczyńska D; Tukiendorf A; Kuliczkowski K; Mazur G
Biomark Med; 2015; 9(5):453-60. PubMed ID: 25620533
[TBL] [Abstract][Full Text] [Related]
2. Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-519.
Blood; 2023 Jun; 141(26):3233. PubMed ID: 37383002
[No Abstract] [Full Text] [Related]
3. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia.
Weng H; Lal K; Yang FF; Chen J
Cancer Genet; 2015 May; 208(5):225-9. PubMed ID: 25686674
[TBL] [Abstract][Full Text] [Related]
4. High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia.
Organista-Nava J; Gómez-Gómez Y; Illades-Aguiar B; Del Carmen Alarcón-Romero L; Saavedra-Herrera MV; Rivera-Ramírez AB; Garzón-Barrientos VH; Leyva-Vázquez MA
Oncol Rep; 2015 Apr; 33(4):1639-49. PubMed ID: 25672522
[TBL] [Abstract][Full Text] [Related]
5. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
6. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
[TBL] [Abstract][Full Text] [Related]
7. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Stone RM; Mazzola E; Neuberg D; Allen SL; Pigneux A; Stuart RK; Wetzler M; Rizzieri D; Erba HP; Damon L; Jang JH; Tallman MS; Warzocha K; Masszi T; Sekeres MA; Egyed M; Horst HA; Selleslag D; Solomon SR; Venugopal P; Lundberg AS; Powell B
J Clin Oncol; 2015 Apr; 33(11):1252-7. PubMed ID: 25732165
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
9. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
[TBL] [Abstract][Full Text] [Related]
10. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
11. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.
Gao XN; Yan F; Lin J; Gao L; Lu XL; Wei SC; Shen N; Pang JX; Ning QY; Komeno Y; Deng AL; Xu YH; Shi JL; Li YH; Zhang DE; Nervi C; Liu SJ; Yu L
Leukemia; 2015 Aug; 29(8):1730-40. PubMed ID: 25727291
[TBL] [Abstract][Full Text] [Related]
12. Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia.
Ecker S; Pancaldi V; Rico D; Valencia A
Genome Med; 2015; 7(1):8. PubMed ID: 25632304
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-331-3p derived from chemoresistant osteosarcoma cells induces chemoresistance through autophagy.
Meng C; Yang Y; Feng W; Ma P; Bai R
J Orthop Surg Res; 2023 Nov; 18(1):892. PubMed ID: 37993925
[TBL] [Abstract][Full Text] [Related]
14. Non-coding RNA-related antitumor mechanisms of marine-derived agents.
Zhou Z; Cao Q; Diao Y; Wang Y; Long L; Wang S; Li P
Front Pharmacol; 2022; 13():1053556. PubMed ID: 36532760
[TBL] [Abstract][Full Text] [Related]
15. The role of exercise-and high fat diet-induced bone marrow extracellular vesicles in stress hematopoiesis.
Vanhie JJ; Kim W; Ek Orloff L; Ngu M; Collao N; De Lisio M
Front Physiol; 2022; 13():1054463. PubMed ID: 36505084
[TBL] [Abstract][Full Text] [Related]
16. miR-331 inhibits CLDN2 expression and may alleviate the vascular endothelial injury induced by sepsis.
Kong L; Wu P; Li J
Exp Ther Med; 2020 Aug; 20(2):1343-1352. PubMed ID: 32742369
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction.
Horváth M; Horváthová V; Hájek P; Štěchovský C; Honěk J; Šenolt L; Veselka J
Sci Rep; 2020 Apr; 10(1):5845. PubMed ID: 32246100
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-331 Inhibits Proliferation and Invasion of Melanoma Cells by Targeting Astrocyte-Elevated Gene-1.
Chen L; Ma G; Cao X; An X; Liu X
Oncol Res; 2018 Oct; 26(9):1429-1437. PubMed ID: 29510779
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.
Trino S; Lamorte D; Caivano A; Laurenzana I; Tagliaferri D; Falco G; Del Vecchio L; Musto P; De Luca L
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401684
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia.
Butrym A; Łacina P; Kuliczkowski K; Bogunia-Kubik K; Mazur G
BMC Cancer; 2018 Jan; 18(1):107. PubMed ID: 29382303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
